Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Large Growth in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the target of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 54,874 shares, a growth of 162.7% from the February 12th total of 20,891 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average trading volume of 174,825 shares, the days-to-cover ratio is presently 0.3 days. Based on an average trading volume of 174,825 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.0% of the shares of the company are short sold.

Analyst Ratings Changes

CMMB has been the subject of several research reports. Zacks Research downgraded Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Chemomab Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Chemomab Therapeutics currently has an average rating of “Hold” and a consensus price target of $25.00.

Chemomab Therapeutics Stock Down 1.6%

Shares of Chemomab Therapeutics stock traded down $0.03 on Friday, hitting $1.83. The stock had a trading volume of 23,252 shares, compared to its average volume of 82,332. The stock has a market cap of $11.27 million, a price-to-earnings ratio of -0.62 and a beta of 0.41. Chemomab Therapeutics has a twelve month low of $1.35 and a twelve month high of $6.10. The business’s 50 day moving average is $1.70 and its two-hundred day moving average is $2.36.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CMMB. Kestra Private Wealth Services LLC acquired a new stake in shares of Chemomab Therapeutics during the fourth quarter worth $85,000. ADAR1 Capital Management LLC acquired a new position in shares of Chemomab Therapeutics in the fourth quarter valued at about $132,000. Finally, XTX Topco Ltd bought a new position in Chemomab Therapeutics during the fourth quarter worth about $31,000. Institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.